{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:47:35Z","timestamp":1793850455398,"version":"4.6.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"48","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Brigham and Women\u2019s Hospital from AstraZeneca."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>In patients with prior myocardial infarction (MI) on aspirin, the addition of ticagrelor reduces ischaemic risk but increases bleeding risk. The simultaneous assessment of baseline ischaemic and bleeding risk may assist clinicians in selecting patients who are most likely to have a favourable risk\/benefit profile with long-term ticagrelor.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>PEGASUS-TIMI 54 randomized 21 162 prior MI patients, 13 956 of which to the approved 60\u2005mg dose or placebo and who had all necessary data. The primary efficacy endpoint was cardiovascular death, MI, or stroke, and the primary safety outcome was TIMI major bleeding; differences in Kaplan\u2013Meier event rates at 3 years are presented. Post-hoc subgroups based on predictors of bleeding and ischaemic risk were merged into a selection algorithm. Patients were divided into four groups: those with a bleeding predictor (n = 2721, 19%) and then those without a bleeding predictor and either 0\u20131 ischaemic risk factor (IRF; n = 3004, 22%), 2 IRF (n = 4903, 35%), or \u22653 IRF (n = 3328, 24%). In patients at high bleeding risk, ticagrelor increased bleeding [absolute risk difference (ARD) +2.3%, 95% confidence interval (CI) 0.6, 3.9] and did not reduce the primary efficacy endpoint (ARD +0.08%, 95% CI \u22122.4 to 2.5). In patients at low bleeding risk, the ARDs in the primary efficacy endpoint with ticagrelor were \u22120.5% (\u22122.2, 1.3), \u22121.5% (\u22123.1, 0.02), and \u22122.6% (\u22125.0, \u22120.24, P = 0.03) in those with \u22641, 2, and 3 risk factors, respectively (P = 0.076 for trend across groups). There were significant trends for greater absolute risk reductions for cardiovascular death (P-trend 0.018), all-cause mortality (P-trend 0.027), and net outcomes (P-trend 0.037) with ticagrelor across these risk groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In a post-hoc exploratory analysis of patients with prior MI, long-term ticagrelor therapy appears to be best suited for those with prior MI with multiple IRFs at low bleeding risk.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trial Registration<\/jats:title>\n                  <jats:p>NCT01225562 ClinicalTrials.gov<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehac402","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T17:11:18Z","timestamp":1668186678000},"page":"5037-5044","source":"Crossref","is-referenced-by-count":25,"title":["Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54"],"prefix":"10.1093","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9860-3584","authenticated-orcid":false,"given":"Marc P","family":"Bonaca","sequence":"first","affiliation":[{"name":"Department of Cardiology and Vascular Medicine, University of Colorado School of Medicine, 2115 N Scranton St Suite 2040, Aurora , CO 80045 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2185-6193","authenticated-orcid":false,"given":"KyungAh","family":"Im","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2852-3474","authenticated-orcid":false,"given":"Giulia","family":"Magnani","sequence":"additional","affiliation":[{"name":"Parma University Hospital , Parma , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Bansilal","sequence":"additional","affiliation":[{"name":"Bayer, Whippany , New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6502-8838","authenticated-orcid":false,"given":"Mikael","family":"Dellborg","sequence":"additional","affiliation":[{"name":"Department of Medicine\/\u00d6stra, Sahlgrenska University Hospital , G\u00f6teborg , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6677-6229","authenticated-orcid":false,"given":"Robert F","family":"Storey","sequence":"additional","affiliation":[{"name":"Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield , Beech Hill Road, Sheffield S10 2RX , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L","family":"Bhatt","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P Gabriel","family":"Steg","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Cit\u00e9, INSERM U-1148 and AP-HP, H\u00f4pital Bichat, FACT (French Alliance for Cardiovascular Trials) Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Cohen","sequence":"additional","affiliation":[{"name":"Newark Beth Israel Medical Center, Rutgers Medical School , Newark, New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9802-4147","authenticated-orcid":false,"given":"Per","family":"Johanson","sequence":"additional","affiliation":[{"name":"AstraZeneca, Gothenburg , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3472-626X","authenticated-orcid":false,"given":"Eugene","family":"Braunwald","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S","family":"Sabatine","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"key":"2022122116273903100_ehac402-B1","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"2022122116273903100_ehac402-B2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"2022122116273903100_ehac402-B3","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2022122116273903100_ehac402-B4","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"2022122116273903100_ehac402-B5","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(19)31887-2","article-title":"Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial","volume":"394","author":"Bhatt","year":"2019","journal-title":"Lancet"},{"key":"2022122116273903100_ehac402-B6","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","article-title":"Ticagrelor in patients with stable coronary disease and diabetes","volume":"381","author":"Steg","year":"2019","journal-title":"N Engl J Med"},{"key":"2022122116273903100_ehac402-B7","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"2022122116273903100_ehac402-B8","doi-asserted-by":"crossref","first-page":"e017008","DOI":"10.1161\/JAHA.120.017008","article-title":"Predictors, type, and impact of bleeding on the net clinical benefit of long-term ticagrelor in stable patients with prior myocardial infarction","volume":"10","author":"Magnani","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2022122116273903100_ehac402-B9","first-page":"1455","article-title":"Management of antithrombotic therapy after bleeding in patients with coronary artery disease and\/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis","volume":"38","author":"Halvorsen","year":"2017","journal-title":"Eur Heart J"},{"key":"2022122116273903100_ehac402-B10","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/eurheartj\/ehr204","article-title":"Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology","volume":"32","author":"Steg","year":"2011","journal-title":"Eur Heart J"},{"key":"2022122116273903100_ehac402-B11","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"2022122116273903100_ehac402-B12","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.jacc.2009.09.076","article-title":"A risk score to predict bleeding in patients with acute coronary syndromes","volume":"55","author":"Mehran","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2022122116273903100_ehac402-B13","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"key":"2022122116273903100_ehac402-B14","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.jacc.2016.03.529","article-title":"Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54","volume":"67","author":"Bhatt","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2022122116273903100_ehac402-B15","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/eurheartj\/ehv531","article-title":"Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54","volume":"37","author":"Bonaca","year":"2016","journal-title":"Eur Heart J"},{"key":"2022122116273903100_ehac402-B16","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","article-title":"Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease","volume":"67","author":"Bonaca","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2022122116273903100_ehac402-B17","first-page":"400","article-title":"Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial","volume":"37","author":"Magnani","year":"2016","journal-title":"Eur Heart J"},{"key":"2022122116273903100_ehac402-B18","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jacc.2017.11.050","article-title":"Ticagrelor for secondary prevention of atherothrombotic events in patients with multivessel coronary disease","volume":"71","author":"Bansilal","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022122116273903100_ehac402-B19","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/ehjcvp\/pvz020","article-title":"Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54","volume":"5","author":"Dellborg","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2022122116273903100_ehac402-B20","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jacc.2017.05.063","article-title":"Cost-Effectiveness of long-term ticagrelor in patients with prior myocardial infarction: results from the PEGASUS-TIMI 54 trial","volume":"70","author":"Magnuson","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2022122116273903100_ehac402-B21","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/9780470743386.ch20","volume-title":"Introduction to meta-analysis","author":"Borenstein","year":"2009"},{"key":"2022122116273903100_ehac402-B22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/archinte.167.1.68","article-title":"External validity of clinical trials in acute myocardial infarction","volume":"167","author":"Steg","year":"2007","journal-title":"Arch Intern Med"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/48\/5037\/48306028\/ehac402.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/48\/5037\/48306028\/ehac402.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T16:54:23Z","timestamp":1671641663000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/43\/48\/5037\/6823782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":22,"journal-issue":{"issue":"48","published-online":{"date-parts":[[2022,11,11]]},"published-print":{"date-parts":[[2022,12,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehac402","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,21]]},"published":{"date-parts":[[2022,11,11]]}}}